

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES  
FINANCIAL STATEMENTS (UNAUDITED)  
AS ON 31ST MARCH 2017 (THIRD QUARTER)**

**ORION PHARMA LIMITED**  
**AND ITS SUBSIDIARIES**  
**Consolidated Statement of Financial Position (Unaudited)**  
**As at 31 March, 2017**

Particulars	Amount In BDT	
	31-Mar-17	30-Jun-16
<b>Assets</b>		
<b>Non-Current Assets</b>	<b>17,899,741,994</b>	<b>18,286,613,234</b>
Property, Plant and Equipment	13,742,706,848	14,058,343,412
Construction Work in Progress	1,712,530,755	1,591,424,708
Investment in Associates	244,979,000	319,403,000
Other Investments	2,199,525,391	2,317,442,114
<b>Current Assets</b>	<b>9,116,051,331</b>	<b>8,603,292,025</b>
Inventories	1,003,197,987	681,075,164
Trade and Other Receivables	6,415,768,906	6,807,087,245
Advances, Deposits & Prepayments	1,463,593,325	872,933,890
Fixed Deposit with Banks	6,972,216	6,757,702
Cash and Cash Equivalents	226,518,897	235,438,024
<b>Total Assets</b>	<b>27,015,793,326</b>	<b>26,889,905,259</b>
<b>Equity and Liabilities</b>		
<b>Shareholders' Equity</b>	<b>16,647,175,202</b>	<b>16,377,819,562</b>
Share Capital	2,340,000,000	2,340,000,000
Share Premium	8,016,892,026	8,016,892,026
Reserves	1,973,148,875	2,083,239,547
Retained Earnings	4,317,134,301	3,937,687,989
Non - Controlling Interest	941,562,335	838,306,456
<b>Total Equity</b>	<b>17,588,737,537</b>	<b>17,216,126,019</b>
<b>Non-Current Liabilities</b>	<b>5,035,696,458</b>	<b>5,663,366,765</b>
Redeemable Preference Share	500,000,000	500,000,000
Long Term Loan	4,287,266,065	4,925,434,529
Provision for Decommissioning of Assets	143,405,563	143,405,563
Employee Benefits Provision	27,550,140	19,989,957
Deferred Tax Liability	77,474,689	74,536,715
<b>Current Liabilities</b>	<b>4,391,359,331</b>	<b>4,010,412,476</b>
Short Term Loan	802,306,748	833,781,938
Trade and Other Payable	2,771,383,431	834,243,837
Accrued Expenses	817,669,153	2,342,386,700
<b>Total equity &amp; Liabilities</b>	<b>27,015,793,326</b>	<b>26,889,905,259</b>
<b>Number of Shares used to compute NAV</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Net Asset Value (NAV) Including Revaluation Surplus</b>	<b>71.14</b>	<b>69.99</b>
<b>Net Asset Value (NAV) Excluding Revaluation Surplus</b>	<b>62.56</b>	<b>61.34</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION PHARMA LIMITED**  
**Statement of Financial Position (Unaudited)**  
**As at 31 March, 2017**

Particulars	Amount In BDT	
	31-Mar-17	30-Jun-16
<b>Assets</b>		
<b>Non-Current Assets</b>	<b>10,032,477,386</b>	<b>9,910,680,476</b>
Property, Plant and Equipment	4,858,442,240	4,665,410,653
Construction Work in Progress	1,712,530,755	1,591,424,709
Investment in Subsidiaries	1,017,000,000	1,017,000,000
Investment in Associates	244,979,000	319,403,000
Other Investments	2,199,525,391	2,317,442,114
<b>Current Assets</b>	<b>5,793,590,497</b>	<b>5,800,753,696</b>
Inventories	283,454,935	299,950,084
Trade and Other Receivables	4,220,729,663	4,774,886,093
Advances, Deposits & Prepayments	1,256,928,500	685,884,662
Fixed Deposit with Banks	6,972,216	6,757,702
Cash and Cash Equivalents	25,505,183	33,275,154
<b>Total Assets</b>	<b>15,826,067,884</b>	<b>15,711,434,172</b>
<b>Equity and Liabilities</b>		
<b>Shareholders' Equity</b>	<b>12,874,470,537</b>	<b>13,191,673,369</b>
Share Capital	2,340,000,000	2,340,000,000
Share Premium	8,016,892,026	8,016,892,026
Reserves	1,537,278,678	1,635,665,548
Retained Earnings	980,299,833	1,199,115,796
<b>Non-current Liabilities</b>	<b>810,783,582</b>	<b>819,728,530</b>
Employee Benefit Provision	27,550,140	19,989,957
Deferred Tax Liability	77,474,689	74,536,715
Long term loan	705,758,752	725,201,858
<b>Current Liabilities</b>	<b>2,140,813,766</b>	<b>1,700,032,273</b>
Short Term Loans	802,306,748	833,781,938
Trade & Other Payables	847,168,218	431,495,332
Accrued Expenses	491,338,800	434,755,003
<b>Total equity &amp; Liabilities</b>	<b>15,826,067,884</b>	<b>15,711,434,172</b>
<b>Number of Shares used to compute NAV</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Net Asset Value (NAV) Including Revaluation Surplus</b>	<b>55.02</b>	<b>56.37</b>
<b>Net Asset Value (NAV) Excluding Revaluation Surplus</b>	<b>48.91</b>	<b>50.22</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION PHARMA LIMITED**  
**AND ITS SUBSIDIARIES**  
**Consolidated Statement of Profit or Loss and Other Comprehensive Income ( Unaudited)**  
**For the 3rd quarter ended 31 March, 2017**

Particulars	Amount In BDT			
	1 July to 31 March 2017	1 July to 31 March 2016	1 January to 31 March 2017	1 January to 31 March 2016
<b>Revenue from Net Sales</b>	<b>6,857,531,666</b>	<b>7,038,589,940</b>	<b>2,306,555,980</b>	<b>2,190,206,934</b>
Cost of Goods Sold	(756,337,658)	(516,738,377)	(300,318,171)	(214,067,165)
Cost of Power Generation	(4,277,589,302)	(4,719,972,660)	(1,471,247,887)	(1,220,199,507)
<b>Gross Profit</b>	<b>1,823,604,706</b>	<b>1,801,878,903</b>	<b>534,989,923</b>	<b>755,940,262</b>
<b>Operating Expenses</b>	<b>(521,340,766)</b>	<b>(418,815,303)</b>	<b>(243,021,092)</b>	<b>(164,855,107)</b>
General & Administrative Expenses	(191,635,774)	(141,439,967)	(92,697,600)	(56,116,452)
Selling & Distribution Expenses	(329,704,992)	(277,375,335)	(150,323,492)	(108,738,655)
<b>Profit from Operation</b>	<b>1,302,263,940</b>	<b>1,383,063,600</b>	<b>291,968,831</b>	<b>591,085,155</b>
Financial Expenses	(477,436,701)	(778,097,185)	(136,394,006)	(497,687,883)
Interest & Other Income	23,750,946	41,633,611	(3,171,335)	2,124,198
<b>Net Profit from Operation</b>	<b>848,578,185</b>	<b>646,600,027</b>	<b>152,403,489</b>	<b>95,521,471</b>
Workers Profit Participation Fund	(7,560,183)	(2,828,281)	(1,756,460)	(1,693,221)
<b>Net Profit before Tax</b>	<b>841,018,002</b>	<b>643,771,745</b>	<b>150,647,029</b>	<b>93,828,250</b>
<b>Income Tax</b>	<b>(36,195,622)</b>	<b>(19,211,378)</b>	<b>(8,504,679)</b>	<b>(16,127,922)</b>
Current Tax Expenses/Income	(34,472,938)	(17,759,781)	(7,623,688)	(16,087,202)
Deferred Tax Expenses	(1,722,684)	(1,451,597)	(880,991)	(40,720)
<b>Net Profit after Tax</b>	<b>804,822,380</b>	<b>624,560,367</b>	<b>142,142,350</b>	<b>77,700,329</b>
Share of Profit from Associate	5,050,200	8,540,301	<b>2,037,800</b>	1,284,700
<b>Net Profit</b>	<b>809,872,580</b>	<b>633,100,668</b>	<b>144,180,150</b>	<b>78,985,029</b>
Less: Non Controlling Interest (share of operating profit)	(103,255,882)	(88,812,147)	(12,134,578)	(2,742,084)
<b>Net Profit after Tax before Other Comprehensive Income</b>	<b>706,616,698</b>	<b>544,288,520</b>	<b>132,045,573</b>	<b>76,242,944</b>
<b>Add: Other Comprehensive Income</b>	<b>(86,261,057)</b>	<b>(25,867,039)</b>	<b>(19,295,868)</b>	<b>(78,293,495)</b>
Fair Value Gain of Marketable Securities	(11,447,524)	(154,589,670)	(6,989,635)	(156,793,095)
Share of Other Comprehensive Income	278,301	22,172,990	(831,483)	21,677,181
Deferred tax income/expense on revaluation Surplus	4,660,667	2,423,331	1,863,089	-
Fair Value Gain on Investment in Associates	(79,752,501)	104,126,310	(16,135,417)	56,822,419
<b>Total Comprehensive Income</b>	<b>620,355,641</b>	<b>518,421,482</b>	<b>112,749,705</b>	<b>(2,050,551)</b>
<b>Attributable to Ordinary Share Holder</b>				
<b>Number of Shares used to compute EPS</b>	<b>234,000,000</b>	<b>234,000,000</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Basic Earning Per Share (EPS)</b>	<b>3.02</b>	<b>2.33</b>	<b>0.56</b>	<b>0.33</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION PHARMA LIMITED**  
**Statement of Profit or Loss and Other Comprehensive Income ( Unaudited)**  
**For the 3rd quarter ended 31 March, 2017**

Particulars	Amount In BDT			
	1 July to 31 March 2017	1 July to 31 March 2016	1 January to 31 March 2017	1 January to 31 March 2016
Revenue from Net Sales	1,477,221,989	1,012,111,374	613,565,274	437,481,464
Cost of Goods Sold	(756,337,658)	(516,738,377)	(300,318,171)	(214,067,164)
<b>Gross Profit</b>	<b>720,884,331</b>	<b>495,372,997</b>	<b>313,247,104</b>	<b>223,414,300</b>
<b>Operating Expenses</b>	<b>(477,427,191)</b>	<b>(368,631,037)</b>	<b>(215,193,833)</b>	<b>(156,595,582)</b>
General & Administrative Expenses	(147,722,199)	(91,255,701)	(64,870,341)	(47,856,927)
Selling & Distribution Expenses	(329,704,992)	(277,375,335)	(150,323,492)	(108,738,655)
<b>Profit from Operation</b>	<b>243,457,140</b>	<b>126,741,960</b>	<b>98,053,271</b>	<b>66,818,718</b>
Financial Expenses	(108,444,249)	(108,981,661)	(57,996,266)	(33,385,275)
Interest & Other Income	23,750,946	41,633,611	(3,171,335)	2,124,198
<b>Net Profit from Operation</b>	<b>158,763,837</b>	<b>59,393,911</b>	<b>36,885,669</b>	<b>35,557,641</b>
Workers Profit Participation Fund	(7,560,183)	(2,828,281)	(1,756,460)	(1,693,221)
<b>Net Profit before Tax</b>	<b>151,203,654</b>	<b>56,565,629</b>	<b>35,129,209</b>	<b>33,864,420</b>
<b>Income Tax</b>	<b>(36,195,622)</b>	<b>(19,211,378)</b>	<b>(8,504,679)</b>	<b>(16,327,921)</b>
Current Tax Expenses	(34,472,938)	(17,759,781)	(7,623,688)	(16,087,201)
Deferred Tax Expenses/ Income	(1,722,684)	(1,451,597)	(880,991)	(240,720)
<b>Net Profit after Tax</b>	<b>115,008,032</b>	<b>37,354,251</b>	<b>26,624,530</b>	<b>17,536,500</b>
Share of Profit from Associates	5,050,200	8,540,301	2,037,800	1,284,700
<b>Net Profit after Tax before Other Comprehensive Income</b>	<b>120,058,232</b>	<b>45,894,552</b>	<b>28,662,330</b>	<b>18,821,200</b>
<b>Add: Other Comprehensive Income</b>	<b>(86,261,065)</b>	<b>(25,867,039)</b>	<b>(22,093,454)</b>	<b>(78,293,495)</b>
Fair Value Gain of Marketable Securities	(11,447,524)	(154,589,670)	(6,989,635)	(156,793,095)
Fair Value Gain on Investment in Associate	(79,752,501)	104,126,310	(16,135,417)	56,822,419
Share of Other Comprehensive Income	278,301	22,172,990	(831,483)	21,677,181
Deferred tax income/expense on revaluation Surplus	4,660,659	2,423,331	1,863,081	-
<b>Total Comprehensive Income attribute to Ordinary Share Holders</b>	<b>33,797,167</b>	<b>20,027,513</b>	<b>6,568,876</b>	<b>(59,472,295)</b>
<b>Number of Shares used to compute EPS</b>	<b>234,000,000</b>	<b>234,000,000</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Basic Earning Per Share (EPS)</b>	<b>0.51</b>	<b>0.20</b>	<b>0.12</b>	<b>0.08</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION PHARMA LIMITED**  
**AND ITS SUBSIDIARIES**  
**Consolidated Statement of Changes in Equity (Unaudited)**  
**For the 3rd quarter ended 31 March, 2017**

Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Retained Earnings	Reserves	Total
<b>Balance at 01 July 2015</b>	2,340,000,000	8,016,892,026	3,582,152,413	2,045,297,387	15,984,341,817
Net Profit after Tax	-	-	544,288,520	-	544,288,520
Prior year adjustment	-	-	7,845,314	-	7,845,314
Fair Value Gain on Investment in Associates	-	-	-	104,126,310	104,126,310
Adjustment for Sale of Land	-	-	-	(92,062,711)	(92,062,711)
Fair Value gain on Marketable Securities	-	-	-	(154,589,670)	(154,589,670)
Adjustment for sale of Mkt. Securities	-	-	-	3,357,693	3,357,693
Share of Other Comprehensive Income	-	-	-	22,172,990	22,172,990
Adjustment for deferred tax on Revaluation Surplus	-	-	-	2,423,331	2,423,331
Adjustment for loss of control from Subsidiaries	-	-	916,640	(916,640)	-
Depreciation on Revaluation Surplus	-	-	26,334,881	(26,334,881)	-
<b>Balance at 31 March 2016</b>	<u>2,340,000,000</u>	<u>8,016,892,026</u>	<u>4,161,537,769</u>	<u>1,903,473,809</u>	<u>16,421,903,595</u>
<b>Balance at 01 July 2016</b>	2,340,000,000	8,016,892,026	3,937,687,989	2,083,239,547	16,377,819,562
Net Profit after Tax	-	-	706,616,698	-	706,616,698
Cash Dividend for the year	-	-	(351,000,000)	-	(351,000,000)
Fair Value Gain on Investment in Associates	-	-	-	(79,752,501)	(79,752,501)
Fair Value gain on Marketable Securities	-	-	-	(11,447,524)	(11,447,524)
Share of Other Comprehensive Income	-	-	-	278,301	278,301
Deferred tax income/expense on revaluation Surplus	-	-	-	4,660,667	4,660,667
Depreciation on Revaluation Surplus	-	-	23,829,614	(23,829,614)	-
<b>Balance at 31 March 2017</b>	<u>2,340,000,000</u>	<u>8,016,892,026</u>	<u>4,317,134,301</u>	<u>1,973,148,875</u>	<u>16,647,175,202</u>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION PHARMA LIMITED**  
**Statement of Changes in Equity (Unaudited)**  
**For the 3rd quarter ended 31 March, 2017**

Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Retained Earnings	Reserves	Total
<b>Balance at 01 July 2015</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>1,093,733,400</b>	<b>1,581,725,294</b>	<b>13,032,350,720</b>
Net Profit after Tax	-	-	45,894,552	-	45,894,552
Prior year adjustment	-	-	7,862,118	-	7,862,118
Fair Value Gain on Investment in Associates	-	-	-	104,126,310	104,126,310
Adjustment for Sale of Land	-	-	-	(92,062,711)	(92,062,711)
Fair Value Loss on Marketable Securities	-	-	-	(154,589,670)	(154,589,670)
Adjustment for sale of Mkt. Securities	-	-	-	3,357,693	3,357,693
Share of Other Comprehensive Income	-	-	-	22,172,990	22,172,990
Adjustment for deferred tax on Revaluation Surplus	-	-	-	2,423,331	2,423,331
Depreciation on Revaluation Surplus	-	-	14,631,078	(14,631,078)	-
<b>Balance at 31 March, 2016</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>1,162,121,147</b>	<b>1,452,522,160</b>	<b>12,971,535,334</b>
<b>Balance at 01 July 2016</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>1,199,115,796</b>	<b>1,635,665,548</b>	<b>13,191,673,369</b>
Net Profit after Tax	-	-	120,058,232	-	120,058,232
Cash Dividend for the year	-	-	(351,000,000)	-	(351,000,000)
Fair Value Gain on Investment in Associates	-	-	-	(79,752,501)	(79,752,501)
Fair Value (Loss)/Gain on Marketable Securities	-	-	-	(11,447,524)	(11,447,524)
Adjustment of deferred tax on revaluation Surplus	-	-	-	4,660,659	4,660,659
Share of Other Comprehensive Income	-	-	-	278,301	278,301
Depreciation on Revaluation Surplus	-	-	12,125,805	(12,125,805)	-
<b>Balance at 31 March, 2017</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>980,299,833</b>	<b>1,537,278,678</b>	<b>12,874,470,537</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION PHARMA LIMITED**  
**AND ITS SUBSIDIARIES**  
**Consolidated Statement of Cash Flows ( Unaudited)**  
**For the 3rd quarter ended 31 March, 2017**

Particulars	Amount In BDT	
	1 July to 31 March 2017	1 July to 31 March 2016
<b>A. Cash Flows from Operating Activities :</b>		
Cash Received from Customers	6,716,377,891	7,935,374,944
Cash paid to Suppliers	(4,329,011,560)	(5,319,013,428)
Cash Payment for Operating Expenses	(346,397,899)	(184,806,487)
<b>Cash Generated from Operation</b>	<b>2,040,968,432</b>	<b>2,431,555,029</b>
Cash Payment for Income Tax	(41,951,768)	(38,406,625)
<b>Net Cash Generated/(Used) from Operating Activities</b>	<b>1,999,016,663</b>	<b>2,393,148,404</b>
<b>B. Cash Flows from Investing Activities :</b>		
Acquisition of Property, Plant & Equipment	(291,266,948)	(63,776,563)
Capital Work in Progress	(121,106,046)	(207,469,025)
Investment in Subsidiaries, Associate & Securities	227,845,366	33,902,144
Investment in FDR	(214,514)	419,711,387
Proceed from sales of property, plant & equipment	-	4,546,008
Interest, Dividend & Other Income	7,282,664	1,307,244
<b>Net Cash Received/(Used) in Investing Activities</b>	<b>(177,459,477)</b>	<b>188,221,195</b>
<b>C. Cash Flows from Financing Activities :</b>		
Long Term Loan Received / (Repaid)	(638,168,464)	(1,132,832,381)
Short Term Loan Received / (Repaid)	(201,629,300)	(625,014,007)
Financial expenses paid	(937,303,707)	(602,810,086)
Dividend paid	(53,374,843)	(273,398,870)
<b>Net Cash Received/(Used) in Financing Activities</b>	<b>(1,830,476,314)</b>	<b>(2,634,055,344)</b>
<b>Net Increase /(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(8,919,127)</b>	<b>(52,685,745)</b>
Cash & Cash Equivalents at the beginning of the year	235,438,024	550,555,534
Cash & Cash Equivalents at the end of the year	<b>226,518,897</b>	<b>497,869,789</b>
<b>Number of Shares used to compute NOCFPS</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Operating Cash Flow Per Share</b>	<b>8.54</b>	<b>10.23</b>

Sd/- <b>Chairman</b>	Sd/- <b>Managing Director</b>	Sd/- <b>Director</b>	Sd/- <b>Chief Financial Officer</b>	Sd/- <b>Company Secretary</b>
-------------------------	----------------------------------	-------------------------	--	----------------------------------



**ORION PHARMA LIMITED**  
**Statement of Cash Flows ( Unaudited)**  
**For the 3rd quarter ended 31 March, 2017**

Particulars	Amount In BDT	
	1 July to 31 March 2017	1 July to 31 March 2016
<b>A. Cash Flows from Operating Activities :</b>		
Cash Received from Customers	1,319,504,753	1,112,473,955
Cash paid to Suppliers	(550,404,934)	(556,227,285)
Cash Payment for Operating Expenses	(346,397,899)	(184,806,487)
<b>Cash Generated from Operation</b>	<b>422,701,920</b>	<b>371,440,183</b>
Cash Payment for Income Tax	(41,951,768)	(38,406,625)
<b>Net Cash Generated/(Used) from Operating Activities</b>	<b>380,750,152</b>	<b>333,033,559</b>
<b>B. Cash Flows from Investing Activities :</b>		
Acquisition of Property, Plant & Equipment	(289,590,204)	(62,287,803)
Capital Work in Progress	(121,106,046)	(207,469,025)
Investment in Subsidiaries, Associate, Securities & Others	227,845,366	33,902,144
Proceed from sales of property, plant & equipment	-	4,546,008
Investment in FDR	(214,514)	419,711,387
Interest, Dividend & Other Income	7,282,665	1,307,244
<b>Net Cash Received/(Used) in Investing Activities</b>	<b>(175,782,733)</b>	<b>189,709,953</b>
<b>C. Cash Flows from Financing Activities :</b>		
Long Term Loan Received / (Repaid)	(19,443,106)	196,337,947
Short Term Loan Received / (Repaid)	(31,475,190)	(277,305,539)
Cash dividend paid	(53,374,843)	(273,398,870)
Interest Paid	(108,444,249)	(100,503,035)
<b>Net Cash Received/(Used) in Financing Activities</b>	<b>(212,737,389)</b>	<b>(454,869,497)</b>
<b>Net Increase/(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(7,769,970)</b>	<b>67,874,015</b>
Cash & Cash Equivalents at the beginning of the year	33,275,154	422,859,123
<b>Cash &amp; Cash Equivalents at the end of the year</b>	<b>25,505,183</b>	<b>490,733,139</b>
<b>Number of Shares used to compute NOCFPS</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Operating Cash Flow Per Share</b>	<b>1.63</b>	<b>1.42</b>

Sd/ -	Sd/ -	Sd/ -	Sd/ -	Sd/ -
Chairman	Managing Director	Director	Chief Financial Officer	Company Secretary

## Orion Pharma Limited

### Selected explanatory notes to the financial Statements as at 31th March, 2017 (3rd Quarter Ended)

#### Reporting entity

Orion Pharma Limited, earlier called Orion Laboratories Limited was incorporated in 1965 as a private limited company. The Company was converted into a public limited company on July 24, 2010. The registered office of the company is at 153-154, Tejgaon I/A, Dhaka-1208, Bangladesh. The consolidated financial statements of the company comprise the company's and its subsidiaries (together referred to as the "Group" and individually as "Group entities") and the Group's interest in associates and jointly controlled entities.

The Company is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE).

Orion Pharma Limited is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products including vaccines, and health-related consumer products.

#### Accounting policies and method of computations

This financial statements are consistent with those used in the annual financial statements, prepared and published for the year ended June 30, 2016 and there have no changes in accounting policy within the interim reporting period.

#### Subsequent events

No material events occurred after the reporting date, non-disclosure of which could affect the ability of the users of the financial statements to make proper evaluation and decision.

#### Disclosure regarding acquisition of fixed assets during the period (PPE) as on 31.03.2017

During the period addition of property plant & equipment is Tk. 289,590,204. Details are hereunder:

SL. NO	Particulars	Addition during the period
1	Factory & Office Building	32,526,282
2	Plant & Machinery	202,712,612
3	Furniture & Fixtures	11,257,395
4	Office Equipment	9,830,215
5	Vehicles	33,263,700
	<b>Total</b>	<b>289,590,204</b>

Sd/ -  
Chairman

Sd/ -  
Managing Director

Sd/ -  
Director

Sd/ -  
Chief Financial Officer

Sd/ -  
Company Secretary